-
公开(公告)号：US07361503B2
公开(公告)日：2008-04-22
申请号：US10985205
申请日：2004-11-09
IPC分类号： C12N15/63
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
公开(公告)号：US20080311150A1
公开(公告)日：2008-12-18
申请号：US12079888
申请日：2008-03-28
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异源二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
公开(公告)号：US06908734B2
公开(公告)日：2005-06-21
申请号：US10323314
申请日：2002-12-19
申请人： Tatjana Dragic , William C. Olson
发明人： Tatjana Dragic , William C. Olson
IPC分类号： A61K38/00 , C07K14/715 , C07K16/28 , C12Q1/70 , A61K39/21 , C07K16/00 , C12N5/00 , C12P21/06
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7158
摘要： This invention provides a compound comprising the structure: θαYDINYYTSEβλ wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein α represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein β represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein θ represents an amino group or an acetylated amino group; wherein λ represents a carboxyl group or an amidated carboxyl group; wherein all of α,Y,D,I,N,Y,Y,T,S,E and β are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.
摘要翻译： 本发明提供了包含以下结构的化合物：其中每个T表示苏氨酸，每个S表示丝氨酸，每个E表示谷氨酸，每个Y表示酪氨酸; 每个D代表天冬氨酸，每个I代表异亮氨酸; 每个N代表天冬酰胺; 其中α代表0至9个氨基酸，条件是如果有多于2个氨基酸，则它们以连续的顺序连接在一起，并具有与SEQ ID NO：1所示的序列相同的序列，以SEQ ID NO： 位置9处的I并在氨基末端方向从其延伸; 其中β代表0至13个氨基酸，条件是如果有多于2个氨基酸，则它们以连接的肽键连接并且具有与SEQ ID NO：1中所示的序列相同的序列，以SEQ ID NO： 位置19处的P并在羧基末端方向从其延伸; 其中theta表示氨基或乙酰化氨基; 其中λ表示羧基或酰胺化的羧基; 其中所有α，Y，D，I，N，Y，Y，T，S，E和β通过肽键连接在一起; 进一步规定化合物中的至少两种酪氨酸被硫酸化。
-
公开(公告)号：US20060194244A1
公开(公告)日：2006-08-31
申请号：US11400497
申请日：2006-04-07
申请人： Graham Allaway , Tatjana Dragic , Virginia Litwin , Paul Maddon , John Moore , Alexandra Trkola
发明人： Graham Allaway , Tatjana Dragic , Virginia Litwin , Paul Maddon , John Moore , Alexandra Trkola
CPC分类号： C07K14/7158 , A01K2217/05 , A61K38/00
摘要： This invention provides a polypeptide comprising a fragment of a chemokine receptor capable of inhibiting HIV-1 infection. In an embodiment, the chemokine receptor is C-C CKR-5. In another embodiment, the fragment comprises at least one extracellular domain of the chemokine receptor C-C CKR-5. This invention further provides different uses of the chemokine receptor for inhibiting HIV-1 infection.
摘要翻译： 本发明提供了包含能够抑制HIV-1感染的趋化因子受体片段的多肽。 在一个实施方案中，趋化因子受体是C-C CKR-5。 在另一个实施方案中，片段包含趋化因子受体C-C CKR-5的至少一个细胞外结构域。 本发明进一步提供趋化因子受体用于抑制HIV-1感染的不同用途。
-
公开(公告)号：US20050266400A1
公开(公告)日：2005-12-01
申请号：US10985205
申请日：2004-11-09
IPC分类号： A61K39/00 , C07H21/02 , C07H21/04 , C07K14/18 , C12N20060101 , C12N7/00 , C12N7/01 , C12Q1/68 , C12Q1/70
CPC分类号： C07H21/02 , A61K2039/5258 , C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2740/13023 , C12N2740/13043 , C12N2740/13045 , C12N2770/24222 , C12N2770/24234 , C12N2810/609 , C12Q1/707
摘要： The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
摘要翻译： 本发明涉及一种修饰的核酸分子，其包含编码选自E1糖蛋白和E1 / E2糖蛋白异二聚体的全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该分子具有至少一个核苷酸改变，其中 由于这种改变，从编码序列中消除了选自RNA剪接受体和RNA剪接供体位点的至少一个RNA剪接位点。 本发明还涉及用于在细胞表面和假病毒表达HCV糖蛋白的方法，其中大部分糖蛋白是全长的。 本发明还提供了表达这种糖蛋白的细胞和假病毒。 本发明还提供了一种用于确定药物是否抑制HCV融合并进入靶细胞的方法。 本发明还提供了抑制HCV融合并进入靶细胞的药剂。 本发明进一步提供了治疗患有HCV相关病症的受试者，用于预防受试者中的HCV感染以及用于在受试者中抑制HCV相关病症发作的方法。
-
公开(公告)号：US06548636B2
公开(公告)日：2003-04-15
申请号：US09796202
申请日：2001-02-28
申请人： Tatjana Dragic , William C. Olson
发明人： Tatjana Dragic , William C. Olson
IPC分类号： A61K3804
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7158
摘要： This invention provides a compound comprising the structure: &thgr;&agr;YDINYYTSE&bgr;&lgr; wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein &agr; represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein &bgr; represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein &thgr; represents an amino group or an acetylated amino group; wherein &lgr; represents a carboxyl group or an amidated carboxyl group; wherein all of &agr;, Y,D,I,N,Y,Y,T,S,E and &bgr; are joined together by peptide bonds; further provided that at least two tyrosines in the compound are sulfated.
摘要翻译： 本发明提供了一种包含以下结构的化合物：其中每个T代表苏氨酸，每个S代表丝氨酸，每个E代表谷氨酸，每个Y代表酪氨酸; 每个D代表天冬氨酸，每个I代表异亮氨酸; 每个N代表天冬酰胺; 其中α代表0至9个氨基酸，条件是如果有多于2个氨基酸，则它们以连续的顺序连接在一起，并具有与SEQ ID NO：1所示的序列相同的序列，以SEQ ID NO： 位置9处的I并在氨基末端方向从其延伸; 其中β代表0至13个氨基酸，条件是如果有多于2个氨基酸，则它们以连接的肽键连接并且具有与SEQ ID NO：1中所示的序列相同的序列，以SEQ ID NO： 位置19处的P并在羧基末端方向从其延伸; 其中theta表示氨基或乙酰化氨基; 其中羔羊代表羧基或酰胺化的羧基; 其中所有α，Y，D，I，N，Y，Y，T，S，E和β通过肽键连接在一起; 进一步规定化合物中的至少两种酪氨酸被硫酸化。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
